Kamada Ltd
KMDA
View Detailed Chart
6.955USD
+0.055+0.80%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
399.95MMarket Cap
21.04P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.80%
5 Days
-0.86%
1 Month
-3.00%
6 Months
+4.43%
Year to Date
+14.20%
1 Year
+31.97%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-18Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
16.000
Target Price
+131.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.
Undervalued
The company’s latest PE is 20.98, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.16M shares, decreasing 3.49% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 832.00K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Ticker SymbolKMDA
CompanyKamada Ltd
CEOMr. Amir London
Websitehttps://www.kamada.com/
Related Instruments
+0.37%
-1.72%
+0.53%
-0.80%
-0.15%
+6.27%
+0.48%
+0.41%
+1.21%
+0.42%
+1.51%
-0.01%
-1.19%
-0.30%
-0.15%
-1.70%
-0.03%
+0.12%
+2.26%
+0.10%
